| Revenue growth | Revenue de-grew 5% YoY to ₹904cr due to business restructuring. |
|---|---|
| Margins | Gross margins improved to 70% from 66% following generic business exit. |
| Demand visibility | Strong for chronic brands; West Asia demand hit by shipping issues. |
| Management confidence | Balanced; focused on integration synergies despite temporary operational slowdown. |
Growth
Branded business grew 8% while chronic segments surged 19%, significantly outperforming market growth despite consolidated revenue pressures.
Outlook
Management expects double-digit India growth and single-digit international recovery starting Q2 FY27 as integration synergies materialize.
Risks
Integration friction, high employee attrition at JB, and West Asia shipping disruptions remain key near-term execution hurdles.
Earnings Call filed with BSE, NSE: JBCHEPHARM. Summary written with AI assistance from the document.
More from J B Chemicals & Pharmaceuticals Ltd
All →Jb Chemicals & Pharmaceuticals Merger & Restructuring
JB Chemicals & Pharmaceuticals' amalgamation with Torrent Pharmaceuticals received NCLT sanction. The scheme will become effective upon filing with the Registrar of Companies.
Jb Chemicals & Pharmaceuticals Management Change
Pradeep Kumar Singh and Suresh Bhise retired from the company. These changes in senior management are effective from June 30, 2026.
Jb Chemicals & Pharmaceuticals Price Movement Clarification
JB Chemicals clarified its audited financial results to the exchange. The board-approved results were signed by a director as authorized.
Jb Chemicals & Pharmaceuticals Management Change
Mr. Bhushan Sachdev resigned as Executive Vice President – Supply Chain Management effective June 12, 2026. Investors should note the departure of a key supply chain executive.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals Limited filed its Business Responsibility and Sustainability Report for FY 2025-26. The report details company ESG performance, sustainability targets, and governance frameworks.
Jb Chemicals & Pharmaceuticals Annual Report
JB Chemicals & Pharmaceuticals filed its FY26 Business Responsibility and Sustainability Report. The filing highlights its ₹3889.89 Crore turnover and ESG progress for investor review.
- Value
- ₹3,890 Cr